Efficacy of Lycium Barbarum Polysaccharide in Dry Eye Disease Management

NCT07842536 | Recruiting

• 1 other identifier: 20260106003
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this pilot clinical study is to learn if Lycium barbarum polysaccharide (LBP) supplementation helps manage dry eye disease in adults. It will also learn about the safety of LBP supplementation. The main questions it aims to answer are:

1. 1.Does LBP supplementation improve dry eye symptoms after 12 weeks?
2. 2.Does LBP supplementation improve clinical signs of dry eye disease, such as tear film stability, tear production, and ocular surface staining?
3. 3.Take LBP tablets by mouth twice daily for 12 weeks
4. 4.Visit the clinic at baseline, 4 weeks, and 12 weeks for checkups and eye tests
5. 5.Complete dry eye questionnaires and undergo clinical assessments of tear film, ocular surface health, and related eye measurements

Conditions

Dry Eye Syndromes

Keywords

Lycium barbarum polysaccharide; LBP; Goji berry; Ocular surface disease; Ocular Surface Disease Index; Dietary supplementation; Dry eye disease; Pilot clinical study

Outcome Measures

Primary Outcomes (1)

• Change in 12-Item Ocular Surface Disease Index Score

  The 12-item Ocular Surface Disease Index (OSDI-12) assesses dry eye symptoms. Scores range from 0 to 100, with higher scores indicating worse symptoms. Change from baseline to Week 12 will be assessed.

  Baseline and Week 12

Secondary Outcomes (8)

• Change in First Non-Invasive Tear Break-Up Time

  Baseline and Week 12

• Change in Tear Film Lipid Layer Thickness

  Baseline and Week 12

• Change in Tear Meniscus Height

  Baseline and Week 12

• Change in Corneal Sensitivity Threshold

  Baseline and Week 12

• Change in Schirmer Test Wetting Length

  Baseline and Week 12

Study Arms (1)

Lycium Barbarum Polysaccharide Supplementation

EXPERIMENTAL

Participants will receive oral Lycium barbarum polysaccharide supplementation for 12 weeks.

Dietary Supplement: Lycium Barbarum Polysaccharide

Interventions

Lycium Barbarum Polysaccharide DIETARY_SUPPLEMENT

Participants will take Lycium barbarum polysaccharide tablets orally for 12 weeks. The dosing regimen is two tablets twice daily, for a total of four tablets per day. Each tablet contains Lycium barbarum glycoconjugates, blueberry powder, and grape seed extract.

Also known as: LBP, Goji glycoconjugates, Viso I

Lycium Barbarum Polysaccharide Supplementation

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Age 18 to 60 years at enrollment.
• Clinical diagnosis of dry eye disease, defined as OSDI-12 score \>=13 and at least one clinical sign of dry eye disease.
• Habitual visual acuity 6/9 or better in both eyes.
• Able to understand the study procedures and provide written informed consent.

You may not qualify if:

• Ocular infection within 3 months before enrollment or ocular disease other than dry eye disease.
• History of ocular surgery, including refractive surgery.
• Use of dry eye-related products, such as artificial tears, within 1 month before enrollment.
• Contact lens wear within 1 month before enrollment.
• Long-term use of medications known to affect dry eye symptoms.
• Severe or unstable systemic disease.
• Infectious disease, such as viral influenza.
• Known allergy or hypersensitivity to Lycium barbarum polysaccharide.
• Pregnant or breastfeeding.
• Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.

Sponsors & Collaborators

• The Hong Kong Polytechnic University: lead

Study Sites (1)

The Hong Kong Polytechnic University, School of Optometry, Optometry Clinic

Hong Kong, Hong Kong, Hong Kong

RECRUITING

MeSH Terms

Conditions

Dry Eye Syndromes

Interventions

lycium barbarum polysaccharide

Condition Hierarchy (Ancestors)

Lacrimal Apparatus Diseases; Eye Diseases

Central Study Contacts

Thomas C LAM, PhD

CONTACT

+852 27666115; thomas.c.lam@polyu.edu.hk

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: September 15, 2026
• First Posted: September 25, 2026
• Study Start: September 14, 2026
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): August 1, 2027
• Last Updated: September 25, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

HK (1)